IL-17 AND IL-23 ANTAGONISTS AND METHODS OF USING THE SAME
First Claim
Patent Images
1. An isolated antibody or antibody fragment that specifically binds a polypeptide comprising SEQ ID NO:
- 2, wherein the antibody binds an epitope selected from the group consisting of;
a) an epitope comprising amino acid residues 34 to 41 of SEQ ID NO;
2; and
b) an epitope comprising amino acid residues 52 to 64 of SEQ ID NO;
2.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it'"'"'s p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
-
Citations
20 Claims
-
1. An isolated antibody or antibody fragment that specifically binds a polypeptide comprising SEQ ID NO:
- 2, wherein the antibody binds an epitope selected from the group consisting of;
a) an epitope comprising amino acid residues 34 to 41 of SEQ ID NO;
2; andb) an epitope comprising amino acid residues 52 to 64 of SEQ ID NO;
2. - View Dependent Claims (2, 3)
- 2, wherein the antibody binds an epitope selected from the group consisting of;
-
4. An isolated antibody or antibody fragment that binds a polypeptide comprising SEQ ID NO:
- 2, wherein the antibody binds an epitope comprising amino acid residues 77 to 85 of SEQ ID NO;
2. - View Dependent Claims (5, 6)
- 2, wherein the antibody binds an epitope comprising amino acid residues 77 to 85 of SEQ ID NO;
-
7. An isolated antibody that binds a polypeptide consisting of the amino acid sequence of SEQ ID NO:
- 4, wherein the antibody binds an epitope selected from the group consisting of;
a) an epitope comprising amino acid residues 55 to 66 of SEQ ID NO;
4; andb) an epitope comprising amino acid residues 74 to 85 of SEQ ID NO;
4. - View Dependent Claims (8, 9)
- 4, wherein the antibody binds an epitope selected from the group consisting of;
-
10. An isolated antibody that binds a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 4, wherein the antibody binds an epitope selected from the group consisting of;
a) an epitope comprising amino acid residues 137 to 146 of SEQ ID NO;
4; andb) an epitope comprising amino acid residues 155 to 164 of SEQ ID NO;
4. - View Dependent Claims (11, 12)
- 4, wherein the antibody binds an epitope selected from the group consisting of;
-
13. An bispecific antibody comprising a first antigen binding site and a second antigen binding site, wherein the first antigen binding site comprises an antibody or antibody fragment that competes with an antibody selected from the group consisting of:
-
a) an antibody comprising a light chain comprising SEQ ID NO;
92 and a heavy chain comprising SEQ ID NO;
93;b) an antibody comprising a light chain comprising SEQ ID NO;
80 and a heavy chain comprising SEQ ID NO;
81;c) an antibody comprising a light chain comprising SEQ ID NO;
128 and a heavy chain comprising SEQ ID NO;
129;d) an antibody comprising a light chain comprising SEQ ID NO;
144 and a heavy chain comprising SEQ ID NO;
145;e) an antibody comprising a light chain comprising SEQ ID NO;
136 and a heavy chain comprising SEQ ID NO;
137;f) an antibody comprising a light chain comprising SEQ ID NO;
96 and a heavy chain comprising SEQ ID NO;
97;g) an antibody comprising a light chain comprising SEQ ID NO;
100 and a heavy chain comprising SEQ ID NO;
101;h) a light chain comprising SEQ ID NO;
124 and a heavy chain comprising SEQ ID NO;
125;i) an antibody comprising a light chain comprising SEQ ID NO;
132 and a heavy chain comprising SEQ ID NO;
133;j) an antibody comprising a light chain comprising SEQ ID NO;
108 and a heavy chain comprising SEQ ID NO;
109; andk) an antibody comprising a light chain comprising the light chain CDR1, CDR2, and CDR3 of any of a)-j), above and a heavy chain comprising the heavy chain CDR1, CDR2, and CDR3 of a)-j), above or competes with an antibody comprising a light chain comprising SEQ ID NO;
148 and a heavy chain comprising SEQ ID NO;
149.for specifically binding a polypeptide consisting of the amino acid sequence of SEQ ID NO;
2;and wherein the second antigen binding site comprises an antibody or antibody fragment that competes with an antibody selected from the group consisting of; a) an antibody comprising a light chain comprising SEQ ID NO;
768 and a heavy chain comprising SEQ ID NO;
769; andb) an antibody comprising a light chain comprising SEQ ID NO;
764 and a heavy chain comprising SEQ ID NO;
765;or competes with an antibody selected from the group consisting of; a) an antibody comprising a light chain comprising SEQ ID NO;
774 and a heavy chain comprising SEQ ID NO;
775; andb) an antibody comprising a light chain comprising SEQ ID NO;
776 and a heavy chain comprising SEQ ID NO;
777;for specifically binding a polypeptide consisting of the amino acid sequence of SEQ ID NO;
2.
-
-
14. An antibody or antibody fragment that binds a polypeptide comprising SEQ ID NO:
- 4, wherein the antibody competes for binding with an antibody comprising a light chain comprising SEQ ID NO;
1014 and a heavy chain comprising SEQ ID NO;
1015 for specifically binding the polypeptide consisting of the amino acid sequence of SEQ ID NO;
4. - View Dependent Claims (15)
- 4, wherein the antibody competes for binding with an antibody comprising a light chain comprising SEQ ID NO;
-
16. A method for inhibiting interleukin-17A (IL-17A) production by T cells comprising treating said T cells with a bispecific antibody comprising a first antigen binding site that specifically binds IL-17A and a second antigen binding site that specifically binds IL-23p19.
- 17. A method for preventing, inhibiting, or reducing relapse in multiple sclerosis comprising administering a bispecific antibody comprising a first antigen binding site that specifically binds IL-17A and a second antigen binding site that specifically binds IL-23p19.
- 19. A method for preventing, inhibiting, or reducing IBD comprising administering a bispecific antibody comprising a first antigen binding site that specifically binds IL-17A and a second antigen binding site that specifically binds IL-23p19.
Specification